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Somatic stem cells mediate tissue maintenance
for the lifetime of an organism. Despite the well-
established longevity that is a prerequisite for such
function, accumulating data argue for compromised
stem cell function with age. Identifying the mecha-
nisms underlying age-dependent stem cell dysfunc-
tion is therefore key to understanding the aging
process. Here, using a model carrying a proof-
reading-defective mitochondrial DNA polymerase,
we demonstrate hematopoietic defects reminiscent
of premature HSC aging, including anemia, lympho-
penia, and myeloid lineage skewing. However, in
contrast to physiological stem cell aging, rapidly
accumulating mitochondrial DNAmutations had little
functional effect on the hematopoietic stem cell pool,
and instead caused distinct differentiation blocks
and/or disappearance of downstream progenitors.
These results show that intact mitochondrial function
is required for appropriate multilineage stem cell
differentiation, but argue against mitochondrial
DNA mutations per se being a primary driver of
somatic stem cell aging.
INTRODUCTION
The hematopoietic system experiences several age-associated
alterations with profound consequences for health, including
reduced immune competence, anemia, and an increased
propensity for hematopoietic cancers (Rossi et al., 2008). In
addition, graft age is by far the most significant negative param-
eter in bone marrow transplantation (Kollman et al., 2001), which
represents perhaps the best example of how age can compro-
mise and influence therapeutic approaches based on regenera-
tive medicine. Several studies have highlighted that intrinsic
molecular differences underlie alterations in HSC function with
age (Rossi et al., 2008). This fact has developed our under-
standing of the manifestations of the aging blood system andinclude an HSC intrinsic loss of differentiation capacity to the
lymphoid lineages and a perturbed reconstitution capacity with
age (Beerman et al., 2010), thereby suggesting HSCs as prime
cellular targets in therapeutic strategies aimed at minimizing
the shortcomings of hematopoietic aging.
While extensive data have been presented on the phenotypes
that associate with hematopoietic aging, less is known about its
underlying cause. The mitochondria of mammalian cells uphold
cellular function and survival by several key processes, which
include oxidative phosphorylation (OXPHOS), various metabolic
processes, and apoptosis. As a remnant of once being symbiotic
bacteria living within early eukaryotes, mitochondria carry their
own genome. This small genome (z16 kb) is replicated indepen-
dently from the nuclear genome and constitutes 37 genes;
13 for subunits of respiratory complexes, 22 tRNAs, and two
rRNAs (Falkenberg et al., 2007). During evolution, remaining
genes necessary for appropriate mitochondrial function have
been transferred or exchanged for homologous genes in the
nucleus, the products subsequently being imported into
the mitochondria to mediate their functions. These include all
the genes of the mitochondrial replication machinery (Falken-
berg et al., 2007). Inherent disorders of mitochondria underlie
several known disruptions in metabolism and can result in
dramatic impairment of organismal health. In the hematopoietic
system, dysfunctional mitochondria have been reported to be
associated with malignant transformation, myelodysplastic
syndrome, and Pearson’s syndrome, as well as more defined
genetic disorders such as X-linked sideroblastic anemia (Fonte-
nay et al., 2006).
Aberrant mitochondrial function might also be particularly
relevant in aging because most, if not all, tissues investigated
thus far experience an age-dependent accumulation of mito-
chondrial DNA (mtDNA) mutations (Larsson, 2010). The demon-
stration that multiple aspects of aging were accelerated in
‘‘mutator’’ mice harboring error-prone forms of themitochondrial
DNA polymerase gamma (POLG) (Kujoth et al., 2005; Trifunovic
et al., 2004) provided direct support for a mitochondrial theory
of aging. However, while these mutator strains presented
phenotypesmimicking premature aging, there is less information
about the direct cellular targets and the fundamental issue of
how accumulating mtDNA mutations might affect somatic stem
cell fate.Cell Stem Cell 8, 499–510, May 6, 2011 ª2011 Elsevier Inc. 499
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Figure 1. Mitochondria Regulation in Early Hematopoietic Differentiation
(A) Schematic representation of hematopoietic development depicting the progenitor cell types characterized in this study.
(B) Heat-map display of RNA expression for key nuclear-encoded mitochondrial-associated genes. Red indicates high while blue indicates low expression in the
indicated cell types (expression levels normalized for each gene across cell types).
(C) Representative MTG profiles of indicated progenitor cells in the absence or presence of Verapamil (MFI; mean fluorescence intensity) (n = 3).
(D) MTG profiles of indicated cell subsets performed in the presence of Verapamil.
(E) Comparison ofMTG profiles and single cell mtDNA qPCRs of indicated progenitors. Open bars: relative MTGMFI (n = 3). Filled bars: relative single cell mtDNA
content in indicated progenitors (n = 89 of each subset). Data were normalized to HSCs and displayed as mean ± SEM.
See also Figures S1 and S4.
Cell Stem Cell
mtDNA Mutations in Blood Cell DifferentiationTo explore the consequences of accumulating mtDNA muta-
tions for the blood system, we performed an extensive charac-
terization of the alterations in hematopoietic stem and progenitor
cell phenotypes and functions in POLG mutator mice. We
demonstrate a severe compromise in early lymphoid and
erythroid development from mutator HSCs, and identify precise
cellular stages where these deficits arise. Surprisingly, these
apoptosis-associated phenotypes were initially independent of
HSC self-renewal and myeloid cell differentiation/proliferation;
the latter, which require continuous production from HSCs due
to their high turnover (Domen et al., 2000). In agreement with
these stage-specific effects, global gene expression studies of
mutator HSCs failed to mimic the molecular alterations that
associate with normal HSC aging (Chambers et al., 2007; Rossi
et al., 2005), with clear alterations in mitochondrial membrane
potential being restricted to affected progenitors. Although500 Cell Stem Cell 8, 499–510, May 6, 2011 ª2011 Elsevier Inc.stressed mutator HSCs, provoked either by serial transplanta-
tion or chronologic age, also severely blunted HSC self-renewal,
their magnitude never approached that observed for lymphopoi-
esis and erythropoiesis. Thereby, our studies highlight the critical
requirement of mitochondrial integrity for multilineage hemato-
poiesis, but segregate normal HSC aging from the primary
consequences of accumulating mtDNA mutations.
RESULTS
Evidence for Differential Mitochondrial Regulation in
Early Hematopoietic Differentiation
To begin to detail mitochondrial regulation at distinct stages of
hematopoietic differentiation (Figure 1A), we first investigated
the RNA expression patterns of a core set of nuclear genes
with established roles in mitochondrial DNA (mtDNA) replication
Cell Stem Cell
mtDNA Mutations in Blood Cell Differentiationand transcription (Figure 1B). Overall, this demonstrated higher
expression of such genes in early erythroid committed progeni-
tors (Figure 1B), although significant expression levels were
observed throughout the investigated cellular stages. Impor-
tantly, these data indicated ongoing mitochondrial regulation in
HSCs, despite the recent observations that HSCs rely more on
anaerobic rather than aerobic respiration for energy metabolism
(Simsek et al., 2010).
We next investigatedmitochondria directly by staining defined
hematopoietic progenitor subsets (Figure 1A) with the fluores-
cent dye Mitotracker Green (MTG), followed by FACS analysis.
MTG localizes to mitochondria regardless of mitochondrial
membrane potential (MMP), and can be used to enumerate the
mitochondrial content in intact cells. However, since MTG has
been reported to be a substrate for multi drug resistance
(MDR) activity (Marques-Santos et al., 2003), we initially exam-
ined the effects of Verapamil, an MDR blocker, on MTG uptake.
This revealed a critical requirement of blocking MDR activity for
efficient MTG uptake, a feature particularly evident in HSCs (Fig-
ure 1C and see Figure S1A available online), which are known to
exhibit high MDR activity (Chaudhary and Roninson, 1991;
Goodell et al., 1997).
MTG staining (in the presence of Verapamil) revealed that
the mitochondrial content was reduced in the transition of
HSCs to bipotent megakaryocytic/erythroid precursor cells
(pre Meg/Es) but gradually increased upon differentiation
through the erythroid committed progenitors pre CFU-Es and
CFU-Es (Figure 1D). Next, to complement the MTG analyses
with an independent method, we quantified mtDNA in a large
spectrum of hematopoietic progenitor cells by single-cell quan-
titative PCR (qPCR) (Figure 1E). Although slightly discrepant with
the MTG profiles for some of the investigated cell types (i.e.,
GMP and MkP), these methods gave highly similar results for
most of the investigated cell types (Figure 1E). Finally, we also
performed qPCR on mtDNA from hematopoietic progenitors
sorted in bulk and normalized for the quantity of genomic DNA
(Wong and Cortopassi, 2002) (Figure S1B), which is a more
traditional, although slightly suboptimal, method for the specific
purpose here, given its dependence on nuclear gene normaliza-
tion and the highly varying cell cycle status among different
progenitor cell subsets (Passegue et al., 2005). Taken together,
these experiments revealed dynamic changes in mtDNA content
upon HSC differentiation, and importantly demonstrated
a relatively highmitochondrial content of HSCs, a cell type other-
wise characterized by low MMP (Simsek et al., 2010).
Accumulating Mitochondrial Mutations Cause
Progressive and Selective Perturbations in Early
Hematopoiesis Distinct from Normal Aging
We next wanted to investigate the hematopoietic dependence
on intact mitochondrial function. To this end, we took advantage
of a mouse strain engineered to express a proofreading-defec-
tive form of POLG (Trifunovic et al., 2004), referred to hereafter
as mutator mice.
We first investigated the hematopoietic progenitor cell compo-
sition of mutator mice and their littermate controls. The cellular
composition of hematopoietic cells in BM and periphery of
young mutator mice (9–12 weeks) were indistinguishable from
their heterozygous or wild-type littermate controls (GLN andDB, data not shown) (Chen et al., 2009; Figure S2). By contrast,
intermediately aged (33–36 weeks old) mutator mice displayed
pronounced alterations in several hematopoietic progenitor cell
compartments (Figure 2), which extended to mature effector
cells (Figure S2). While no changes were observed in the
frequency of HSCs (Figure 2A),mutatormice presented a striking
increase of pre Meg/Es (5.8-fold) and pre CFU-Es (24.5-fold)
(Figures 2B and 2C). To allow for correlation to more advanced
age, we conducted similar analysis on 100-week-old mice,
although this precluded evaluation of mutator mice that do not
reach this age (Trifunovic et al., 2004). In sharp contrast to inter-
mediately aged mutator mice, advanced aged WT mice did not
display an accumulation of either pre Meg/Es or pre CFU-Es
(Figures 2B and 2C), but exhibited pronounced increases in
HSC numbers, in agreement with previous studies (Rossi et al.,
2005). These data established that the defect in erythropoiesis
observed in mutator mice (Chen et al., 2009; Trifunovic et al.,
2004; Figure S2) associated with a severe differentiation block
at defined stages of early erythroid development (Figure 2C),
which segregated from normal physiologic aging (Figures 2B
and 2C).
Apart from defective erythropoiesis, mutator mice have also
been reported to display perturbations in lymphopoiesis in an
age-dependent manner (Chen et al., 2009). However, in contrast
to erythropoiesis, where the earliest stages of development were
affected (Figures 2B and 2C), the most primitive lymphoid-
restricted populations remained unaffected with intact frequen-
cies of common lymphoid progenitors (CLPs), B cell-biased
lymphoid progenitors (BLP) (Inlay et al., 2009), and Pre/ProB
cells (Figure 2D). This was strikingly different from the physiolog-
ically aged setting, which was characterized by reduced
frequencies of all these progenitors (Figure 2D). By contrast,
ProB cells (defined by a B220+CD19+IL7Ra+ phenotype) were
dramatically reduced in intermediately aged mutator mice, while
B220+CD19+IL7Ra cells, which include recirculating B cells,
were less affected (Figures 2E and 2F). Again, aged WT con-
trasted these phenotypes (Figures 2E and 2F).
Mitochondrial DNA Mutations Compromise the
Multilineage and Self-Renewal Capacity of
Hematopoietic Stem Cells in an Asynchronous Manner
To assess HSC function of mutator mice, we isolated and
transplanted candidate HSCs from young CD45.1 mutator
mice or their littermate controls into young CD45.2 wild-type
mice. To allow quantification, we performed these experiments
in a competitive manner (Harrison, 1980). Test-cell-derived
reconstitution was observed in all recipients regardless of their
genotype (Figure 3A). HSCs from wild-type mice efficiently
supported high levels of long-term reconstitution of all blood
cell lineages. By contrast, severe perturbations were observed
in the ability of mutator HSCs to repopulate the B and T cell
lineages (Figure 3A), although, importantly, all recipients ofmuta-
tor HSCs contained some levels of donor-derived B and T cells.
Heterozygous mutator HSCs displayed an intermediate pheno-
type (Figure 3A), suggesting a gene dosage effect in this setting.
It is well known that transplantation enforces enhanced
HSC cycling (Allsopp et al., 2001) and serial transplantation
can therefore be used to expose genetic phenotypes with subtle
HSC phenotypes in the steady state, since this eventuallyCell Stem Cell 8, 499–510, May 6, 2011 ª2011 Elsevier Inc. 501
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Figure 2. Mitochondria Mutations Alter the Hematopoietic Differentiation Capacity of Mutator Mice in a Time-Dependent Manner, but are
Distinct from Normal Hematopoietic Aging
(A) HSC frequencies in 9- to 12-week-old and 33- to 36-week-old wild-type, heterozygous, or homozygousmutator and aged wild-type (100weeks) bonemarrow
(mean values ± SEM, n = 3–5).
(B) Myeloid progenitor cell frequencies in 33- to 36-week-old and 100-week-old mice of indicated genotypes (data points refer to frequencies in individual mice).
(C) Representative FACSplots ofmyeloid progenitors in bonemarrow of 33- to 36-week-oldwild-type (left panel), mutator mice (middle panel), and agedWTmice
(100 weeks) (right panel), which highlight the pronounced accumulation of mutator pre CFU-E cells.
(D) Lymphoid progenitor frequencies measured by FACS in mid-aged and agedmice (100 weeks) of indicated genotypes, with each data point referring to values
in individual mice.
(E) B cell restricted progenitor frequencies (pre-gated on B220+CD19+ cells) in mid-aged and aged mice of indicated genotypes, with each data point referring to
values in individual mice.
(F) FACS plots illustrating the decrease of IL7Ra+ ProB cells (boxed) in mutator mice.
See also Figure S2.
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mtDNA Mutations in Blood Cell Differentiationexhausts the HSC function even of wild-type HSCs (Harrison
et al., 1978). This was especially relevant in the context of the
mutator model, as the hematopoietic phenotypes of these
mice arise in a strict time-dependent manner in steady state (Fig-
ure 2 and Figure S2). We used a strategy where 1 3 106 young
WT or mutator CD45+ BM cells were transplanted noncompeti-
tively into a set of lethally irradiated WT hosts. From these
primary hosts, we isolated donor-derived HSCs 16 weeks after
transplantation and transferred these cells into lethally irradiated
secondary hosts in competition with WT BM cells. In this setting,
mutator HSCs exhibited a 6.7-fold lower contribution to mature
blood cells as compared to the transplantedWT cells (Figure 3B).
We also conducted experiments where mid-agedWT or mutator
HSCs were isolated and competitively transplanted into lethally
irradiated hosts. The observed phenotype of mutator HSCs in
this setting (Figure 3C) was highly reminiscent of serially trans-
planted mutator HSCs (Figure 3B).
Mature peripheral erythrocytes do not express the CD45
marker that is used to distinguish between test and compet-
itor/host-derived blood cells of other lineages. Thus, to expose
potential alterations in the erythroid lineage in the primary trans-
plantation setting, we turned our attention to the bone marrow
where immature erythroid progenitors express detectable levels
of the CD45 marker up to the CFU-E stage. These analyses re-
vealed that mutator-derived erythroid progenitor reconstitution
(pre CFU-Es and CFU-Es) was strongly diminished (2.8-fold;502 Cell Stem Cell 8, 499–510, May 6, 2011 ª2011 Elsevier Inc.Figure 3D) 16 weeks after transplantation, demonstrating that
the HSC defects of mutator mice include the erythroid lineage
(Figure 3D). We next sought to directly confirm the ongoing
HSC self-renewal. To this end, HSC recipients were sacrificed
16 weeks after transplantation to allow for an investigation of
the HSC-derived progenitor compartments. These data demon-
strated an indistinguishable regeneration of mutator HSCs as
compared to their littermate controls (Figure 3D). Upon extensive
proliferation caused by serial transplantation of mutator HSCs,
there is a further decline in their erythroid potential while reten-
tion of an apparent, although reduced, capacity to self-renew
(Figure 3E). The dependence of intact mitochondrial function
for appropriate lympho- and erythropoiesis could be extended
also to an in vitro situation (Figure S3).
Taken together, these data demonstrate that the hematopoi-
etic lineage defects in mutator mice are caused by functional
alterations in lineage-restricted progenitor cells rather than at
the level of HSCs. However, extensive proliferation of mutator
HSCs upon regenerative stress and aging ultimately cause
a functional decline also in HSC self-renewal.
The Consequences of Accumulating Mitochondrial
DNA Mutations for Mitochondrial Function
Because of themaintained HSC activity of mutator mice, despite
the severe functional compromise at downstream progenitor
levels, we next directly evaluated the mtDNA mutation rates in
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Figure 3. The Altered Hematopoiesis of Mutator Mice has a Hematopoietic Stem Cell Autonomous Origin
(A) One hundred Linckit+Sca1+CD34/loFlt3CD150+ cells isolated from mutator mice or littermates (CD45.1) were transplanted per mouse into lethally
irradiated C57BL/6 WT mice (CD45.2), together with a competitive dose of 300,000 unfractionated C57BL/6 bone marrow cells. Peripheral blood was analyzed
for donor contribution at given time points (mean ± SEM, n = 8 to 9 recipients per group).
(B) 106 unfractionated BM cells from mutator cells or their wild-type littermate controls were used to reconstitute the blood system of primary lethally irradiated
C57BL/6 hosts. Long-term after transplantation (16 weeks), HSCs (Linckit+Sca1+CD34/loFlt3CD150+) were isolated from the bone marrow of primary
recipients, after which they were transplanted at 500 cells/mouse together with 300,000 C57Bl/6 unfractionated bone marrow cells. Shown is the total contri-
bution in individual mice 16 weeks post-transplantation, with reference lines indicating the group mean.
(C) Five hundred LinSca1+ckit+CD150+CD48 isolated from aged mutator mice or littermates (33 to 34 weeks) were transplanted competitively into lethally
irradiated WT recipient mice. Shown is the total contribution in individual mice 16 weeks post-transplantation, with reference lines indicating the group mean.
(D) Donor contribution to the erythroid and HSC progenitor pools in bone marrow 6 months after primary transplantation. Data show individual recipients with
reference lines indicating group mean value.
(E) Donor contribution to the erythroid and HSC progenitor pools in bone marrow 6 months after initiation of secondary transplantations. Data show levels in
individual mice, with reference lines indicating group mean value.
See also Figure S3.
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mtDNA Mutations in Blood Cell DifferentiationHSCs. For comparison, we also evaluated mutation rates in pre
CFU-Es, a cell type severely affected in mutator mice. To obtain
sufficient sequencing depth, we PCR-amplified mtDNA frag-
ments from single-sorted HSCs and pre CFU-Es (Figure 4A).
While the majority of the mtDNA mutations were heteroplasmic
(Figure 4A, left panel), the results further demonstrated higher
and similar mutation frequencies of both mutator HSCs andpre CFU-Es compared to their littermate control cells. Thus,
HSCs in mutator mice display comparable levels of mutations
as their downstream progeny.
To begin to unravel the functional consequences of increased
mtDNA mutations on the phenotypes of hematopoietic subpop-
ulations, we next determined the effect of increased mtDNA
mutation load on mitochondrial membrane potential (MMP) byCell Stem Cell 8, 499–510, May 6, 2011 ª2011 Elsevier Inc. 503
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Figure 4. Hematopoietic Progenitor Cells from Mutator Mice Display with Increased Mitochondrial DNA Mutation Loads and Altered
Mitochondrial Membrane Potential Leading to Lineage Specific Increases in Apoptosis
(A) Single HSCs and pre CFU-Es were sorted from WT and mutator mice (30 weeks old) into lysis buffer and subjected to PCR with primers directed against
a portion of mitochondrial DNA, followed by sequencing (30–43 individual sequences obtained per cell type). Left panel: Representative sequence data. Note the
heteroplasmic nature of mutation. Middle panel: Calculated mutation frequencies in the indicated progenitors (mean ± SEM). Right panel: Summary of mutation
types.
(B) Indicated cell typeswere treated with the ion uncoupler CCCP that disrupts themitochondriamembrane potential or the F0/F1 ATPase inhibitor Oligomycin, as
indicated. Displayed data are from one of three experiments with similar results (data show mean ± SEM).
(C) Two hundred and fifty HSCs and pre CFU-Es were isolated in triplicates from mutator and littermate mice (39 weeks) and subjected to ATP measurements
(data show mean ± SEM, n = 3).
(D) Indicated progenitor cell subsets were evaluated for ROS levels by DCFH-DA staining and enumerated by FACS. Data show representative FACS plots of ROS
levels in indicated progenitor subsets from mutator or control mice (29 weeks) (analysis performed on three mice/genotype).
(E) Indicated progenitor subsets were isolated and cultured (HSCs, GMPs, and pre CFU-Es were cultured for 3 days in suspension while GMLPs were cocultured
with OP9 stromal cells for 11 days), followed by determination of the ratio of apoptotic cells by FACS following Annexin V and PI staining (data show mean ± SD
from three to four mice/genotype).
Cell Stem Cell
mtDNA Mutations in Blood Cell Differentiation
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mtDNA Mutations in Blood Cell DifferentiationJC-1 stainings of defined progenitor subsets. These experiments
demonstrated that, regardless of genotype, HSCs displayed
lower MMP than both GMs and pre CFU-Es, whereas pre
CFU-Es showed the highest MMP (Figure 4B). Mutator HSCs,
GMs, and pre CFU-Es all displayed slightly lower MMP
compared to their WT counterparts (Figure 4B). As mitochondria
sustain the MMP through the proton-transporting activity of
the oxidative respiratory chain complexes (Huttemann et al.,
2008), we speculated that decreased MMP was a result of
reduced OXPHOS activity as has been previously been
observed in skeletal muscle cells using an independent mutator
strain (Hiona et al., 2010). To test this hypothesis, we treated
cells with Oligomycin, an F0-ATPase inhibitor that blocks the
activity of Complex V of the oxidative phosphorylation chain,
which results in accumulation of protons in the mitochondrial
intermembrane space and therefore an increasedMMP. Despite
that both mutator HSCs and GMs displayed lower MMP thanWT
cells upon Oligomycin treatment, both these cell types showed
similar increase in MMP compared to WT cells (Figure 4B).
Strikingly, however, the mitochondria of mutator pre CFU-Es
failed to raise the MMP to levels observed with WT progenitors
(Figure 4B). Mitochondria of all cells investigated lost their
membrane potential upon treatment with the ion uncoupler
CCCP (Figure 4B).
As the mitochondrial proton gradient is harnessed for the
synthesis of ATP, we speculated that the different MMP between
the different progenitor subsets could have a differential depen-
dence on ATP produced byOXPHOS. Sincemutator pre CFU-Es
displayed both a lowered MMP and an abnormal response to
Oligomycin, we hypothesized that the observed differential block
at this cellular stage was due to a defective ATP synthesis in
these cells. Somewhat surprisingly however, mutator cells did
not appear to exhibit different levels of intracellular ATP when
compared to WT cells (Figure 4C). According to the mitochon-
drial theory of aging, mtDNA accumulates mutations due to
oxidation by mitochondrial-derived ROS, an accumulation of
mutations that augments further ROS production (Harman,
1972). However, in agreement with previous studies using
in vitro cultured or other terminally differentiated cell types, we
did not observe any difference in ROS levels between WT and
mutator hematopoietic progenitor cells (Figure 4D).
Lowered MMP correlates with cells undergoing apoptosis,
and cells overexpressing the antiapoptotic protein BCL-2 exhibit
an increase in MMP (Gogvadze et al., 2006). We therefore next
decided to investigate if we could find any evidence of elevated
apoptosis rates of mutator cells. HSCs, GMPs, and pre CFU-Es
were cultured for 3 days in suspension cultures, while GMLPs
were cultured on OP9 stromal cells for 11 days in order to allow
for B cell development. On the last day of culture, cells were
harvested and stained with Annexin V and/or propidium iodide
(PI) to measure apoptosis. These experiments revealed that
HSCs display lower rates of apoptosis than other cell types,
a feature independent of genotype (Figure 4E), further supporting
our findings that HSCs remain mostly unaffected by the mutator
genotype. In agreement with our transplantation data, both
mutator and littermate GMPs exhibit comparable levels of
apoptosis (Figure 4E). Strikingly however, mutator pre CFU-Es
andB cells displayed an almost 2-fold increase of apoptotic cells
(Figure 4E).The Phenotypic and Molecular Features of Mutator
Hematopoietic Stem Cells are Distinct from Normal
Physiological Aging
The HSC compartment undergoes a range of functional and
phenotypic alterations with age (Rossi et al., 2005). As mutator
mice have been described as a model of premature aging, we
therefore next set out to detail how well this correlated to the
setting of physiological HSC aging.
A recently identified hallmark of normal HSC aging is an
accumulation and striking dominance within the candidate
HSC pool of a definedmyeloid-biased subset of HSCs (Beerman
et al., 2010). Such cells can be prospectively identified based on
their high expression of Slamf1 (CD150). Given the myeloid-
biased output from mutator mice and similarities shared with
physiologically aged HSCs (Figure 5A), we investigated young
(10–12weeks), mid-aged (33 to 34weeks), and aged (100weeks)
mutator and control mice for HSC subset composition. These
experiments revealed a gradual age-dependent elevation in the
myeloid-biased Slamf1hi HSC subset (Figure 5B), independent
of genotype. Thus, despite the pronounced myeloid-biased
output of mutator HSCs (Figure 5A), only small differences
were observed in HSC subset distribution (Figure 5C), while as
previously reported (Beerman et al., 2010), physiological aging
was associated with a striking dominance of the myeloid-biased
Slamf1hi HSC subset.
To further our comparison of mutator HSCs to those of
physiologically aged HSCs, we next evaluated the ATP levels
(Figure 5D), ROS production (Figure 5E), and MMP (Figure 5F)
of young and aged WT HSCs. While none of these parameters
were altered in aged HSCs, this was in contrast to mutator
HSCs that showed a consistent reduction in MMP (Figure 4).
Although the mechanisms underlying HSC aging remain to be
fully revealed, normally aged WT HSCs have a characteristic
global gene expression signature (Chambers et al., 2007; Rossi
et al., 2005). Because we, throughout these studies, used
a slightly different phenotype to identify candidate HSCs
compared to previous studies, and to further our analyses on
potential similarities between normal physiologic aging and the
premature aging phenotypes of mutator mice, we isolated RNA
from candidate LinSca1+ckit+CD150+CD48 HSCs sorted
from young (9–12 weeks) and aged (>2 year old) WT mice and
subjected it to Affymetrix 430.2 gene chip analysis. Next, we
conducted similar experiments on RNA isolated from HSCs
from mid-aged mutator mice or their wild-type littermate
controls.
To define the shift in gene expression that associated with
physiological HSC aging, we first analyzed the gene chip data
for how many genes displayed a 2-fold change in expression in
young WT HSCs compared to the aged WT HSCs. With this
stringent criterion, 35 probe sets exhibited lower expression
and 140 probe sets were upregulated in the aged HSCs, while
11,095 displayed less than a 2-fold difference (Figure 5G; Table
S1). Next, we executed the same analysis on HSCs derived
from the mutator and littermate mice. In striking contrast to
normal HSC aging, this revealed only two genes to be either
up- or downregulated in mutator HSCs (Figure 5G; Table S1).
We also subjected our microarray data to Gene Set Enrichment
Analysis, which is a method to determine whether defined gene
sets might display statistically significant differences betweenCell Stem Cell 8, 499–510, May 6, 2011 ª2011 Elsevier Inc. 505
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Figure 5. Hematopoietic Stem Cells of Mutator Mice; Fundamental Differences to the Setting of Physiologically Aging
(A) Lineage contribution following transplantation of mutator and WT HSCs at different ages. Pie charts show average contribution of HSCs from indicated
sources to each indicated lineage 4 months after transplantation (n = 6–8 recipients/group).
(B) Representative FACS plots of bone marrow cells stained with antibodies against lineage antigens, Sca1, ckit, Flt3, CD150, and CD34 to identify myeloid-
biased HSCs. Displayed are lineageSca1+ckit+Flt3 pregated cells.
(C) Frequency enumeration of Slamf1hi (myeloid-biased) and Slamf1lo HSCs in individual mice.
(D) Two hundred and fifty HSCs from young (10–14 weeks) and aged (100 weeks) WT mice were subjected to ATP measurement (n = 3 mice for each genotype).
Data show mean values ± SEM.
(E) Young (10–14 weeks) and aged (100 weeks) HSCs were evaluated for ROS levels by DCFH-DA staining. Representative FACS plots from three independent
experiments.
(F) JC-1 staining of young (10–14 weeks) and aged (100 weeks) HSCs with or without Oligomycin. Data show mean values ± SEM (n = 3).
(G) RNAwas extracted from sorted HSCs, followed by linear amplification, and hybridized to Affymetrix 430 2.0 arrays (triplicate arrays/condition). Venn diagrams
are displayed with the number of genes that were 2-fold or higher differentially expressed in aged versus young WT HSCs and mutator (32 weeks) versus WT
littermate HSCs (32 weeks), respectively.
(H) The 140 gene HSC aging-associated signature was assessed with GSEA for correlation to the expression profiles of aged versus young WT HSCs in an
independent training set (left panel), and mutator versus littermate HSCs (right panel).
See also Table S1.
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this method is based on the fact that it concentrates on gene
sets that share a common biological property (in this case,
age) instead of focusing merely on the difference between
individual genes. Thus, this method should have the capacity
to reveal subtler changes in gene expression that cannot be
revealed by the stringent analysis criteria used in our primary
analyses. We focused on the 140 genes that became upregu-
lated upon physiological aging and investigated the gene chip
data of mutator HSCs and their littermate controls for correlation
to these genes. As an independent training set, we performed
the same analysis on a previously published gene chip data
set on young and aged WT HSCs (Chambers et al., 2007). While506 Cell Stem Cell 8, 499–510, May 6, 2011 ª2011 Elsevier Inc.it displayed highly significant correlation to the aged training set
(Figure 5H, left panel), this analysis failed to reveal any significant
differences in the gene expression patterns ofmutator HSCs and
their littermate controls (Figure 5H, right panel). Thus, the molec-
ular features of HSC aging are fundamentally different from those
arising as a consequence of accumulating mtDNA mutations.
Taken together, these data revealed a fundamental difference
between normal HSC aging and the premature aging pheno-
types of mutator HSCs. The lineage skewing associated with
normal aging appeared to have an underlying genetic/epigenetic
basis at the HSC level, possibly caused by the selective expan-
sion of a class of myeloid-biased HSCs (Figure 5C), but with little
evidence of functional alterations that affect mitochondrial
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lower MMP (Figure 4), but no apparent differences in global
gene expression.
DISCUSSION
The aging blood system experiences profound changes in both
the types of effector cells generated as well as the function of
produced cells. Combined, such changes lead to a compromise
in adaptive immunity, underlie anemia, and cause decreased
stress responses (Rossi et al., 2008). Many, if not all, of the
changes in hematopoietic regenerative capacity with age are
coupled to an altered functional capacity of HSCs, which appear
to havemultiple mechanistic foundations, including the accumu-
lation of macromolecular damage, epigenetic dysregulation,
and/or a clonal selection for myeloid biased cells (Beerman
et al., 2010; Chambers et al., 2007; Morales et al., 2005; Nijnik
et al., 2007; Rossi et al., 2005, 2007).
In the adult, HSCs remain relatively inactive (Passegue et al.,
2005), and most data argue that the primitive compartment of
hematopoietic cells that includes HSCs relies more on glycolysis
as opposed to OXPHOS as the primary means of ATP synthesis
(Simsek et al., 2010; Unwin et al., 2006). However, OXPHOS is
only one of many roles executed bymitochondria. By addressing
the distribution of mitochondria in highly defined hematopoietic
progenitor cells, hypothesizing that mitochondrial numbers
might serve as a general indicator of the cellular dependence
of various mitochondrial processes, we exposed different
levels of mitochondria as a result of early hematopoietic differen-
tiation. Importantly, among the primitive subsets studied, HSCs
carry relatively high levels of mitochondria, although these are
less active, at least when evaluating MMP.
Mice with defective mitochondrial polymerase gamma
(‘‘mutator’’ mice) exhibit multiple premature aging phenotypes,
including osteoporosis, weight loss, thymic involution, and
anemia (Trifunovic et al., 2004). These phenotypes arise gradu-
ally along with accumulating mitochondrial mutations. Here we
identified several defined developmental stages in hematopoi-
esis, where the mutator genotype leads to prominent perturba-
tions, including an increase/block of early erythropoiesis (at the
pre CFU-E stage) and a reduction of B cell committed progenitor
cells (ProB) (Figure 2). However, HSC frequencies of mutator
mice did not diverge from those of wild-type mice, evidenced
further by an intact production of myeloid cells, which has
previously been demonstrated to serve as a good indicator of
maintained HSC function (Domen et al., 2000). Therefore, indi-
vidual hematopoietic lineages call upon separate mechanisms
in order to fulfill the metabolic requirements required for their
appropriate differentiation. Hence, the bottlenecks in differentia-
tion caused by insufficient mitochondrial function are traceable
to defined stages of hematopoietic development. This situation
appears very similar to differentiation of embryonic stem cells,
where differentiation is accompanied by an in initial decrease
followed by a rapid increase in mitochondrial numbers, which
correlate with an increased OXPHOS dependence (Facucho-
Oliveira and St John, 2009).
Although it has previously demonstrated that mutator mice
associate with a high mitochondrial DNA mutation load, it is also
clear that this mutational load differs between tissues (Vermulstet al., 2007). As we demonstrate here, pre CFU-Es, which are
severely affected by the mutator genotype (Figure 2C), display
a mutation load very similar to that of HSCs (Figure 4A). Although
this demonstrates that HSCs do indeed succumb to accumula-
tion of mitochondrial DNA mutations in mutator mice, our data
do not exclude the possibility that HSCs are, to some extent,
guarded against the accumulation of mitochondrial mutations
due to their relative quiescence or glycolytic metabolism.
Alternatively, or complementary, it might also well be that the
mutation load varies depending on the proliferation properties
of the tissue, with the blood system representing a highly prolif-
erative tissues, whereas previous studies have mainly focused
on postmitotic tissues such as cardiac muscle or neurons of
the brain.
Eosinophils generate their MMP through hydrolysis of ATP
rather than from oxidative respiration. Therefore, treatment
with the F0/F1 ATPase inhibitor Oligomycin does not result in
increased MMP of such cells (Peachman et al., 2001), akin to
what we observed for mutator pre CFU-Es. However, despite
the absence of respiration observed in eosinophils, their mito-
chondria actively participate in the regulation of apoptosis
(Peachman et al., 2001). We hypothesized that pre CFU-Es
were highly reliant onmitochondrial respiration for ATP synthesis
given the extent of their perturbation in mutator mice and based
on their high-level expression of nuclear genes of the OXPHOS
chain (Figure S4). We did, however, fail to observe a difference
in intracellular ATP levels between mutator and WT pre CFU-Es
(Figure 4C), somewhat in contrast to previous studies onmutator
cells (Hiona et al., 2010; Trifunovic et al., 2004). Although our
studies do not exclude the possibility that mutator pre CFU-Es
display a reduced ATP synthesis by OXPHOS and are able to
compensate by, for instance, anaerobic glycolysis, we rather
favor that, in contrast to a postmitotic tissue such as muscle,
the blood is a highly mitotic tissue that relies on constant output
of progenitor cells throughout life. Therefore, as mitochondrial
mutations accumulate, progenitor cells that rely on intact mito-
chondrial function will be unable to proliferate/differentiate,
subsequently be eliminated, and therefore not present with
noticeable differences in ATP levels when evaluated in vivo.
Several genetically modified animals that model physiological
aging are available and have been the subject of intense study
(Morales et al., 2005; Nijnik et al., 2007; Rossi et al., 2007).
However, common for most, if not all, of these model animals
is that they fail to mimic the multifactorial aspects of aging. The
validity of mutator mice as a model-system for physiological
aging can be questioned as accumulation of mtDNA mutations
in this strain has been shown to bemore than amagnitude higher
when compared to various human tissue from aged individuals
(Khrapko et al., 2006). Additionally, another mutator strain failed
to recreate the multiple aspects of normal skeletal muscle aging
(Hiona et al., 2010). In agreement with this, while mimicking
certain phenotypes associated with HSC aging, including
development of lymphopenia and anemia, a distinct functional
discrepancy emerges between HSC activity of mutator mice
and that of physiologically aged HSCs, evidenced by the
absence of a molecularly aged phenotype and epigenetic
alteration of mutator HSCs (Figure 5). Although this does not
exclude that mitochondrial mutations are a contributing factor
in physiological aging, our studies do demonstrate that severeCell Stem Cell 8, 499–510, May 6, 2011 ª2011 Elsevier Inc. 507
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HSC-aging phenotypes despite having staggering conse-
quences at distinct downstream progenitor levels. Our data
therefore highlight the importance of probing mitochondrial
integrity and function, combined with exploration of mitochon-
dria-based therapies, in the development of therapeutic modal-
ities based on HSCs.
EXPERIMENTAL PROCEDURES
Mice
Two- to nine-month-old heterozygous Polgtm1Lrsn mice (a kind gift from Nils-
Go¨ran Larsson; Trifunovic et al., 2004) were backcrossed with CD45.1+
C57BL/6 mice for four generations. Littermate siblings were used as controls
throughout these studies. For some experiments not involvingmutatormice (in
Figure 1 and Figure 5), young (10–12 weeks) or aged (24 months) C57BL/6J
were used. All mice procedures were performed with consent from the local
ethics committee.
Immunophenotypic Analysis and Cell Sorting
Isolation and analysis of hematopoietic stem cells and lymphoid progenitors
by FACS were performed as described (Inlay et al., 2009; Pronk and Bryder,
2011; Pronk et al., 2007). Myeloid-biased Slamf1hi HSCs (Figure 5) were
identified as described (Beerman et al., 2010). Cells were sorted and analyzed
on a FACS Aria cell sorter (Becton Dickinson, Franklin Lakes, NJ). All flow
cytometry and FACS data were analyzed with FlowJo software (Treestar,
Ashland, OR).
Peripheral Blood
Peripheral blood was collected from the tail vein in Microvette tubes (Sarstedt,
Nu¨rmbrecht, Germany) and analyzed on a Sysmex KX-21 Nmachine (Sysmex,
Norderstedt, Germany).
In Vivo Reconstitution Experiments
Competitive repopulation experiments using the congenic CD45.1/CD45.2
mouse model were performed as described previously (Pronk et al., 2007).
For reconstitution analysis of transplanted recipients, chimerism was calcu-
lated as the percentage of donor contribution within the specified lineages.
Bone marrow HSC chimerism levels were evaluated similarly by individual
isolation of BM cells from each recipient followed by staining for HSC and
progenitor markers, in addition to antibodies against CD45.1 and CD45.2 to
distinguish test cells from competitor cells/host cells.
For serial transplantation experiments, 106 unfractionated BM cells from
mutator mice or their wild-type littermate controls were transplanted into
irradiated C57BL/6 hosts. Sixteen weeks after transplantation, HSCs
(LinSca1+ckit+CD34/loCD150+) were isolated from the bone marrow of
primary recipient and transplanted at 500 cells/mouse together with 300,000
C57BL/6 bone marrow cells.
CFU-S8 capacity of FACS sorted pre Meg/E cells was evaluated as
described (Pronk et al., 2007).
In Vitro Culture Assays
Freshly isolated hematopoietic stem and progenitor cells were cultured in
standard culture conditions (37C, 98% humidity, and 5% CO2) in OptiMEM
(Invitrogen, Carlsbad, CA) supplemented with 10% FCS in the presence
of SCF (50 ng/ml), IL3 (10 ng/ml, Peprotech Inc.), and erythropoietin
(EPO; 5 U/ml; Janssen-Cilag, Bersee, Belgium) to evaluate clonogenic activity
and lineage potentials of isolated cell populations. Myeloid and B cell potential
of GMLPs was evaluated by sorting GMLPs directly onto OP9 stromal sup-
ported cultures, as described (Pronk et al., 2008). Pre CFU-Es were sorted
and cultured in OptiMEM supplemented with 10% FCS in the presence of
SCF (50 ng/ml), IL3 (10 ng/ml), and EPO (5 U/ml). Total cell numbers were
counted after 3 days of culture to calculate erythroid output. For apoptosis
assays, cells were sorted and cultured in OptiMEM supplemented with 10%
FCS in the presence of SCF (50 ng/ml), IL3 (10 ng/ml), and EPO (5 U/ml) as
above. After culture, cells were incubated with Annexin V (Becton Dickinson,
Franklin Lakes, NJ) and Propidium Iodide (Invitrogen, Carlsbad, CA) according508 Cell Stem Cell 8, 499–510, May 6, 2011 ª2011 Elsevier Inc.to manufacturer’s instructions and directly evaluated by flow cytometry to
obtain the frequency of Annexin V-positive cells.
ROS Assay
ROS levels weremeasured in ckit-enriched bonemarrow cells (MACS,Miltenyi
Biotech, Bergisch Gladbach, Germany) stainedwith antibodies to defineHSCs
and progenitors. Cells were subsequently incubated in 5 mM DCFH-DA (Invi-
trogen, Carlsbad, CA) for 30 min at 37C and analyzed by FACS immediately
after staining.
ATP Quantification
ATP was quantified using the ATP bioluminescent somatic cell assay kit
(Sigma-Aldrich, St. Louis, MO) following manufacturer’s recommendations. In
short, cells were sorted into PBS and 3.9 3 1013 moles of ATP standard
was added to standard samples. Directly following isolation, cells were
incubated with the ATP releasing agent (Sigma-Aldrich, St. Louis, MO) and
illumination was immediately quantified with a Glomax Illuminator (Promega,
Madison, WI).
Mitochondrial Quantification and mtDNA Sequencing
Cells were sorted into lysis buffer containing Proteinase K and incubated at
50C for 60 min followed by 4 min at 99C. Samples were diluted in water
and subjected to quantitative PCR as described (Attema et al., 2009) with
primers directed against genomic or mitochondrial DNA using MyiQ iCycler
(Biorad, Hercules, CA). For mtDNA sequencing, single cells were sorted and
treated as above, following PCR amplification with primers directed against
mtDNA (Fw: 50-GTTATTAGGGTGGCAGAGCCAG-30, Rev: 50-GCCCGATAG
CTTAATTAGCTGAC-30; region 2673–3873, GenBank: V00711) and Phusion
Hot Start II High-Fidelity Polymerase (Thermo Fisher, Waltham, MA). PCR
amplified fragments were thereafter purified and sequenced by Eurofins
MWG Operon (Ebersberg, Germany).
For mitochondrial quantification by FACS, bone marrow cells were stained
with antibodies to define HSCs and progenitors. Cells were subsequently
stained in the presence of 50 mM Verapamil (Sigma-Aldrich, St. Louis, MO)
with 20 nM MitoTracker Green (Invitrogen, Carlsbad, CA) according to manu-
facturer’s recommendations and analyzed by FACS immediately after
staining.
Membrane Potential Evaluation
Mitochondrial membrane potential was evaluated in bone marrow samples
depleted of cells positive for lineage markers and enriched for cells expressing
ckit. Following antibody staining to identify HSCs and progenitors, cells
were incubated in OptiMem supplemented with 10% FCS in the presence of
SCF (10 ng/ml), TPO (10 ng/ml), and IL3 (5 ng/ml) for 3 hr at standard culture
conditions. Following 2 hr in culture, selected samples were cultured for 1 hr
in the presence of 5 mg/ml Oligomycin (Sigma-Aldrich, St. Louis, MO) or
for 5 min in 5 mM carbonyl cyanide 3-chlorophenylhydrazone (CCCP)
(Sigma-Aldrich, St. Louis, MO). Subsequently, all samples were incubated
in the presence of 5 mM Verapamil for 10 min, after which samples were
stained with the lipophilic, cationic dye JC-1 (Cayman Chemical Company,
Ann Arbor, MI) at 1/1000 dilution according to manufacturer’s recommenda-
tions, followed by FACS analysis.
Affymetrix Gene Expression Analysis and Quantitative RT-PCR
RNA was extracted in triplicates for each group from 4000–7000 HSCs with
RNeasy-micromRNApurification kit (QIAGEN), as previously described (Pronk
et al., 2007). Subsequent handling was performed at the Stanford PAN facility
(http://cmgm.stanford.edu/pan/). The microarray data in Figure 1B and
Figure S4 can be found in the Gene Expression Omnibus (Pre Meg/E,
Pre CFU-E, CFU-E, MkP and CLP, accession number GSE8407) (GMLP,
accession number GSE18734) (ProB, accession number GSE14833) and the
Training Set Data in Figure 5D (accession number GSE6503).
For subsequent analysis, probe level expression values were extracted
using RMA and analyses were done using dChip software (http://biosun1.
harvard.edu/complab/dchip/) following filtering out probes with a lower
expression than 100 in all subsets to eliminate noise in expression.
Quantitative RT-PCR experiments were performed as described (Attema
et al., 2009).
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gene-aging list usingGene Set Enrichment Analysis (Subramanian et al., 2005).
Statistics
Results were statistically analyzed and figures prepared using Excel and
GraphPad Prism (GraphPad Inc.) software. A two-tailed Student’s t test was
used throughout to evaluate statistical significance. Significance is indicated
as follows: *p < 0.05, **p < 0.001, and ***p < 0.0001.
ACCESSION NUMBERS
The GEO accession numbers for the microarray data reported in this paper are
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